<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc. (“Novelion"), headquartered in Vancouver, British Col...

    Novelion Therapeutics Inc. (“Novelion"), head...

    Filing Type:    PU
    ChemoCentryx, Inc.

    ChemoCentryx, Inc.

    ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...

    ChemoCentryx is a biopharmaceutical company foc...

    Filing Type:    PU
    Betterpath, Inc.

    Betterpath, Inc.

    Betterpath makes the benefit of health data ownership clear, reconciling crucial s...

    Betterpath makes the benefit of health data own...

    Amount Raised:    $8,800,000
    Fundraising Status:    EC
    Filing Type:    CF
    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...

    Cyclerion Therapeutics is a clinical-stage biop...

    Filing Type:    PU
    ChemoCentryx, Inc.

    ChemoCentryx, Inc.

    ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...

    ChemoCentryx is a biopharmaceutical company foc...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    Chimerix, Inc.

    Chimerix, Inc.

    Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...

    Chimerix is a development-stage biopharmaceutic...

    Filing Type:    PU
    MEI Pharma, Inc.

    MEI Pharma, Inc.

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...

    Filing Type:    PU
    ProLung, Inc.

    ProLung, Inc.

    ProLung is a medical technology company specializing in innovative predictive anal...

    ProLung is a medical technology company special...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.